doi;PMID;section;ITC num;Ind studies num;questions;reviewer 1;reviewer 2;decision;identical;Notes reviewer 1;Notes reviewer 2
10.1093/europace/euy160;30052894;general_information;;;Medical Condition of Interest Name;;;non-valvular atrial fibrillation;TRUE;NA;NA
10.1093/europace/euy160;30052894;general_information;;;Countries of first author affiliations;;;uk;TRUE;;
10.1093/europace/euy160;30052894;general_information;;;Countries of last author affiliations;;;canada;TRUE;;
10.1093/europace/euy160;30052894;general_information;;;Positions of study investigators (for any authors of the article, any that applies);;;Academic, Pharmaceutical Industry, Private Data Analysis Company;TRUE;;
10.1093/europace/euy160;30052894;general_information;;;At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company;;;Yes;TRUE;;
10.1093/europace/euy160;30052894;general_information;;;Mentioned sources of funding;;;Pharmaceutical Industry;TRUE;;
10.1093/europace/euy160;30052894;general_information;;;Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article;;;Yes;TRUE;;
10.1093/europace/euy160;30052894;general_information;;;Mention of a systematic review to find the studies to compare treatments of interest;;;No;TRUE;;
10.1093/europace/euy160;30052894;study_information;;1;Patient-level data used;;;Yes;TRUE;;
10.1093/europace/euy160;30052894;study_information;;1;Clinical Trial;;;No;TRUE;;
10.1093/europace/euy160;30052894;study_information;;1;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01606995;TRUE;;
10.1093/europace/euy160;30052894;study_information;;1;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.1093/europace/euy160;30052894;study_information;;2;Patient-level data used;;;No;TRUE;;
10.1093/europace/euy160;30052894;study_information;;2;Clinical Trial;;;Yes;TRUE;;
10.1093/europace/euy160;30052894;study_information;;2;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT00403767;TRUE;;
10.1093/europace/euy160;30052894;study_information;;2;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.1093/europace/euy160;30052894;study_information;;2;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.1093/europace/euy160;30052894;study_information;;2;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Treatment name 1;;;rivaroxaban;TRUE;RCT vs RWD, to compare efficacy/safety of same treatment in different populations;"To compare results from RWD and a clinical trial

""CHADS2 score and gender were selected as relevant variables for adjustment, as these encompass most of the relevant risk factors for stroke whilst also including a large enough number of patients to enable a meaningful analysis. ""  ==> risk factors and not prognostic factors ???"
10.1093/europace/euy160;30052894;methodology;1;;Study 'number(s)' for treatment 1;;;1;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Treatment name 2;;;rivaroxaban;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Study 'number(s)' for treatment 2;;;2;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Anchored comparison?;;;No;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Form of the indirect comparison;;;Simple (ie treatments effects extracted from two studies);TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Definition of a single primary outcome for the indirect comparison;;;No primary outcome defined, or multiple primary outcomes without any clear distinction between them;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);treatment-emergent adjudicated major bleeding;annualized incidence rate of major bleeding;treatment-emergent adjudicated major bleeding;FALSE;;
10.1093/europace/euy160;30052894;methodology;1;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.1093/europace/euy160;30052894;methodology;1;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Sample size of the population of interest in the non IPD treatment arm;;;7061;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Initial sample size of the population of interest in the IPD treatment arm;;;4020;TRUE;;
10.1093/europace/euy160;30052894;results;1;;"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";;;2492;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Reporting of the list of the covariates adjusted for/matched on;;;Yes;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Number of covariates adjusted for/matched on;;;2;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Covariates adjusted for/matched on in the indirect comparison;Age, Sex;Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease);Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease);FALSE;;
10.1093/europace/euy160;30052894;results;1;;Primary outcome: treatment effect contrast;;;RR;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.1093/europace/euy160;30052894;results;1;;Primary outcome: adjusted treatment effect;;;0.86;TRUE;;
10.1093/europace/euy160;30052894;results;1;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";;;"[0.67;1.12]";TRUE;;
